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Follow-up was performed at 30 days, 6 months, 1 year, and yearly thereafter. All events
were defined according to VARC criteria.
Results: Women undergoing TAVI were older compared to men (80.85.9 vs. 78.28.6
years, p0.01), but had less coronary and peripheral arterial disease and higher ejection
fraction. The logistic EuroSCORE was comparable (23.113.8% vs. 25.716.2%, p0.20).
Aortic annular diameter (22.71.9 vs. 24.22.2 mm, p0.001) and valve size were smaller
in women. After TAVI, mean residual aortic pressure gradient was similar (9.46.2 vs.
8.74.4, p0.38), but significant (2/4) paravalvular aortic regurgitation was less frequent in
women (15.1% vs. 28.1%, p0.01), resulting in a higher device success rate. Despite more
frequent peri-procedural life-threatening bleeding and major vascular complications in women
(11.9% vs. 4.2%, p0.04, and 9.5% vs. 0%, p0.002), mortality was numerically lower in
women at 30-days (3.2% vs. 5.2%, p0.44) and significantly lower at 6 months (6.6% vs.
15.5%, p0.04) and one year (7.7% vs. 21.4%, p0.01). Survival rates at 3 years were 83.1%
in women and 60.5% in men (log-rank p0.02).
Conclusions: Women undergoing TAVI are older but have less co-morbidities compared
to men. Bleeding and vascular complications are more common in women, but significant
aortic regurgitation occurs less. Women have improved mid-term survival after TAVI and
thus appear to obtain a greater benefit from this evolving procedure.
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Background: Trans-catheter aortic valve replacement (TAVR) is a procedure known to
have a higher radiation dose compared to coronary intervention. It is a new alternative
treatment for symptomatic aortic stenosis in patients who are considered high risk or
inoperable for conventional surgical aortic valve replacement. The radiation exposure in
these procedures should be kept as low as reasonably achievable (ALARA). The range of
radiation dose during this procedure is largely unknown. In this single centre prospective
analysis, we determined whether lower fluoroscopy and cine imaging settings would be
safe, showing lower radiation doses while maintaining an acceptable image quality during
TAVR procedures.
Methods: Data on radiation exposure was prospectively collected for consecutive
patients undergoing TAVR at our centre. The fluoroscopic and cine-acquisition settings
were changed from coronary to electrophysiology (EP) settings in the same cardiac
algorithm using a Philips Allura Xper FD 10 single plane C-arm. This resulted in a
reduction for fluoroscopy, from 15 pulse-progressive fluoroscopy (ppf) to 3.75 – 7.5 ppf
and for cine acquisition, from 15 frames per sec (fps) to 3.75 – 7.5 fps for access site
management.
Results: Data for 57 consecutive patients was collected over a period of 8 months from
the Royal Victoria Hospital, Belfast. 29 patients (13 males) with a mean age of 83 (range
63-91 years) and mean BMI-27.4 (range 19-42) underwent TAVR using SS. 28 patients
(12 males) with a mean age of 81 (range 64-93 years) and mean BMI-27.6 (range 17-44)
underwent TAVR using LS. The median dose area product using the lower setting was
8786 cGy*cm2 as compared to 12658 cGy*cm2 for the standard group which was
statistically significant (p-value  0.0257). The screening time, procedure time and
contrast were not significant statistically. There were no procedural deaths or radiation
burns in either group at 30 days follow-up.
Conclusions: This study demonstrates a significant reduction in radiation dose with the
new settings while preserving acceptable image quality. However, radiation exposure still
remains higher compared to PCI due to length and complexity of this procedure.
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Background: Transcatheter aortic valve implantation (TAVI) is revolutionizing treat-
ment of aortic stenosis. While Edwards Sapien and Medtronic CoreValve have emerged
at the forefront, other TAVs are in first-in-man trials for dissemination. Development of
patient-specific computational simulations of TAVI will become important for optimizing
TAV choice for a given patient. The aim of this study was to develop a computational
platform for modeling TAVI in a patient-specific manner.
Methods: ECG-gated computed tomography (CT) was performed on severe aortic
stenosis patient. MicroCT was performed of excised valve. 3D mesh geometry of aortic
root and valve were generated to create finite element (FE) model. Computer aided design
(CAD) TAV model was developed based on 23mm Edwards-SAPIEN design. TAV
consisted of stainless steel stent, 3 pericardial leaflets, clamp compression unit and
expandable balloon. FE simulations were conducted using LS-DYNA to model TAV
crimping and balloon-expansion to annulus dimension and leaflet loading to 80mmHg
diastolic pressure. Stress distribution on TAV stent and leaflets were determined.
Results: Mesh of patient-specific aortic root and calcified valve are shown in fig1a/ b.
Numerical TAVI simulation was successfully conducted (Fig 1c).
Conclusions: Patient-specific simulations of TAVI will become a crucial part of the
clinical paradigm to optimize TAV choice and sizing for a given aortic annulus.
Minimizing stent and leaflet stresses while reducing paravalvular leakage will become
important tools for optimizing success of TAVI.
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